Sign-up for our monthly newsletter!

Sign-up for the M&A Perspective Newsletter!

Sign-up for the Arbitration Case Alert Newsletter!

 
Deals & Cases

Schellenberg Wittmer successfully represented Actavis in patent litigation against Eli Lilly

09.03.2017 – Actavis, an affiliate of Teva Pharmaceutical Industries, one of the leading pharmaceutical companies worldwide, was successfully represented in a patent litigation by Schellenberg Wittmer’s IP Team (lead counsel Andrea Mondini) against Eli Lilly.

After having dismissed Eli Lilly's request for preliminary injunctions, the Swiss Federal Patent Court granted Actavis a declaratory judgment on the merits that Actavis' pemetrexed diacid product does not infringe Eli Lilly's patent EP 1 313 508 B1 claiming pemetrexed disodium for cancer treatment. This patent is heavily litigated in several countries, including Germany and the United Kingdom.